Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More
Dr. Reddy's is a leading pharmaceutical company in the country with presence across the pharmaceutical value chain - basic research, finished dosages, generics, bulk actives, and biotechnology. The company's business is mainly organized into Global g... More
ALEMBIC | DR. REDDYS LAB | ALEMBIC/ DR. REDDYS LAB |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 60.3 | 35.4 | 170.3% | View Chart |
P/BV | x | 5.2 | 4.8 | 107.3% | View Chart |
Dividend Yield | % | 0.2 | 0.5 | 35.8% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ALEMBIC Mar-18 |
DR. REDDYS LAB Mar-20 |
ALEMBIC/ DR. REDDYS LAB |
5-Yr Chart Click to enlarge
|
||
High | Rs | 72 | 3,363 | 2.1% | |
Low | Rs | 34 | 2,352 | 1.4% | |
Sales per share (Unadj.) | Rs | 4.7 | 1,054.2 | 0.4% | |
Earnings per share (Unadj.) | Rs | 6.1 | 121.9 | 5.0% | |
Cash flow per share (Unadj.) | Rs | 6.2 | 190.2 | 3.3% | |
Dividends per share (Unadj.) | Rs | 0.20 | 25.00 | 0.8% | |
Dividend yield (eoy) | % | 0.4 | 0.9 | 43.2% | |
Book value per share (Unadj.) | Rs | 40.7 | 938.7 | 4.3% | |
Shares outstanding (eoy) | m | 267.03 | 166.17 | 160.7% | |
Bonus/Rights/Conversions | - | ESOP | - | ||
Price / Sales ratio | x | 11.3 | 2.7 | 415.6% | |
Avg P/E ratio | x | 8.7 | 23.4 | 37.0% | |
P/CF ratio (eoy) | x | 8.5 | 15.0 | 56.4% | |
Price / Book Value ratio | x | 1.3 | 3.0 | 42.8% | |
Dividend payout | % | 3.3 | 20.5 | 16.0% | |
Avg Mkt Cap | Rs m | 14,139 | 474,831 | 3.0% | |
No. of employees | `000 | NA | 21.7 | 0.0% | |
Total wages/salary | Rs m | 207 | 33,802 | 0.6% | |
Avg. sales/employee | Rs Th | NM | 8,091.0 | - | |
Avg. wages/employee | Rs Th | NM | 1,561.3 | - | |
Avg. net profit/employee | Rs Th | NM | 935.8 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 1,255 | 175,170 | 0.7% | |
Other income | Rs m | 370 | 6,206 | 6.0% | |
Total revenues | Rs m | 1,625 | 181,376 | 0.9% | |
Gross profit | Rs m | 111 | 24,421 | 0.5% | |
Depreciation | Rs m | 38 | 11,348 | 0.3% | |
Interest | Rs m | 2 | 983 | 0.2% | |
Profit before tax | Rs m | 442 | 18,296 | 2.4% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 1,212 | 561 | 216.0% | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 24 | -1,403 | -1.7% | |
Profit after tax | Rs m | 1,630 | 20,260 | 8.0% | |
Gross profit margin | % | 8.9 | 13.9 | 63.5% | |
Effective tax rate | % | 5.4 | -7.7 | -70.7% | |
Net profit margin | % | 129.8 | 11.6 | 1,122.7% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 1,867 | 125,991 | 1.5% | |
Current liabilities | Rs m | 591 | 72,141 | 0.8% | |
Net working cap to sales | % | 101.6 | 30.7 | 330.7% | |
Current ratio | x | 3.2 | 1.7 | 180.8% | |
Inventory Days | Days | 94 | 73 | 129.0% | |
Debtors Days | Days | 74 | 105 | 70.2% | |
Net fixed assets | Rs m | 1,791 | 83,854 | 2.1% | |
Share capital | Rs m | 534 | 831 | 64.3% | |
"Free" reserves | Rs m | 10,324 | 155,157 | 6.7% | |
Net worth | Rs m | 10,858 | 155,988 | 7.0% | |
Long term debt | Rs m | 41 | 1,304 | 3.2% | |
Total assets | Rs m | 11,591 | 232,253 | 5.0% | |
Interest coverage | x | 260.9 | 19.6 | 1,330.2% | |
Debt to equity ratio | x | 0 | 0 | 45.4% | |
Sales to assets ratio | x | 0.1 | 0.8 | 14.4% | |
Return on assets | % | 14.1 | 9.1 | 153.9% | |
Return on equity | % | 15.0 | 13.0 | 115.6% | |
Return on capital | % | 15.2 | 12.6 | 120.4% | |
Exports to sales | % | 1.5 | 0 | - | |
Imports to sales | % | 21.0 | 0 | - | |
Exports (fob) | Rs m | 19 | NA | - | |
Imports (cif) | Rs m | 263 | NA | - | |
Fx inflow | Rs m | 19 | 84,193 | 0.0% | |
Fx outflow | Rs m | 264 | 39,616 | 0.7% | |
Net fx | Rs m | -244 | 44,577 | -0.5% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 236 | 29,841 | 0.8% | |
From Investments | Rs m | -224 | -4,923 | 4.6% | |
From Financial Activity | Rs m | -27 | -25,159 | 0.1% | |
Net Cashflow | Rs m | -15 | -266 | 5.6% |
Indian Promoters | % | 64.0 | 25.5 | 251.0% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 0.2 | 5.4 | 3.7% | |
FIIs | % | 9.7 | 35.3 | 27.5% | |
ADR/GDR | % | 0.0 | 18.5 | - | |
Free float | % | 26.1 | 15.3 | 170.6% | |
Shareholders | 54,701 | 75,885 | 72.1% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare ALEMBIC With: DISHMAN PHARMA ELDER PHARMA SUVEN LIFE SCIENCES DR. DATSONS LABS WOCKHARDT
Compare ALEMBIC With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Share markets in India are presently trading on a negative note. The BSE Sensex is trading down by 385 points, down 0.8% at 51,059 levels.
For the quarter ended June 2020, ALEMBIC LTD has posted a net profit of Rs 21 m (up 3.5% YoY). Sales on the other hand came in at Rs 131 m (down 49.7% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.
For the quarter ended June 2019, ALEMBIC LTD has posted a net profit of Rs 20 m (down 70.9% YoY). Sales on the other hand came in at Rs 260 m (down 41.5% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.
For the quarter ended March 2019, ALEMBIC LTD has posted a net profit of Rs 40 m (down 14.6% YoY). Sales on the other hand came in at Rs 253 m (down 23.8% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.
For the quarter ended June 2019, ALEMBIC LTD has posted a net profit of Rs 20 m (down 70.9% YoY). Sales on the other hand came in at Rs 260 m (down 41.5% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.
For the quarter ended March 2019, ALEMBIC LTD has posted a net profit of Rs 40 m (down 14.6% YoY). Sales on the other hand came in at Rs 253 m (down 23.8% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.
More Views on NewsLast time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.
In this video, I'll show you how to get started on the path to daily trading profits.
In this episode, ace trader Brijesh Bhatia talks to us about the best investments of 2021, his profitable trading system, and much more.
An Indian company founded three decades ago in a garage caught my attention...
More